Novavax, Inc. (NVAX)
NVAX Stock Price Chart
Explore Novavax, Inc. interactive price chart. Choose custom timeframes to analyze NVAX price movements and trends.
NVAX Company Profile
Discover essential business fundamentals and corporate details for Novavax, Inc. (NVAX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Dec 1995
Employees
952.00
Website
https://www.novavax.comCEO
John Charles Jacobs
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVAX Financial Timeline
Browse a chronological timeline of Novavax, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.22.
Earnings released on 6 Aug 2025
EPS came in at $0.62 surpassing the estimated -$0.07 by +985.71%, while revenue for the quarter reached $239.24M , beating expectations by +363.74%.
Earnings released on 8 May 2025
EPS came in at $2.93 surpassing the estimated $0.71 by +312.68%, while revenue for the quarter reached $666.66M , beating expectations by +93.88%.
Earnings released on 27 Feb 2025
EPS came in at -$0.51 surpassing the estimated -$0.75 by +32.00%, while revenue for the quarter reached $88.31M , beating expectations by +4.66%.
Earnings released on 12 Nov 2024
EPS came in at -$0.76 surpassing the estimated -$0.87 by +12.64%, while revenue for the quarter reached $84.51M , missing expectations by -7.05%.
Earnings released on 8 Aug 2024
EPS came in at $0.99 falling short of the estimated $1.64 by -39.63%, while revenue for the quarter reached $415.48M , missing expectations by -9.40%.
Earnings released on 10 May 2024
EPS came in at -$1.05 falling short of the estimated -$1.04 by -0.96%, while revenue for the quarter reached $93.86M , missing expectations by -7.22%.
Earnings released on 28 Feb 2024
EPS came in at -$1.44 falling short of the estimated -$0.49 by -193.88%, while revenue for the quarter reached $291.34M , missing expectations by -9.51%.
Earnings released on 9 Nov 2023
EPS came in at -$1.26 surpassing the estimated -$1.82 by +30.77%, while revenue for the quarter reached $22.06M , missing expectations by -93.14%.
Earnings released on 8 Aug 2023
EPS came in at $0.58 surpassing the estimated -$1.39 by +141.73%, while revenue for the quarter reached $424.43M , beating expectations by +77.47%.
Earnings released on 9 May 2023
EPS came in at -$3.41 falling short of the estimated -$3.38 by -0.89%, while revenue for the quarter reached $80.95M , missing expectations by -7.60%.
Earnings released on 28 Feb 2023
EPS came in at -$2.28 falling short of the estimated -$0.92 by -147.83%, while revenue for the quarter reached $287.83M , missing expectations by -24.88%.
Earnings released on 8 Nov 2022
EPS came in at -$2.15 falling short of the estimated $2.21 by -197.29%, while revenue for the quarter reached $734.58M , beating expectations by +25.30%.
Earnings released on 8 Aug 2022
EPS came in at -$6.53 falling short of the estimated $5.51 by -218.51%, while revenue for the quarter reached $185.93M , missing expectations by -78.47%.
Earnings released on 9 May 2022
EPS came in at $2.56 falling short of the estimated $2.69 by -4.83%, while revenue for the quarter reached $703.97M , missing expectations by -16.71%.
Earnings released on 28 Feb 2022
EPS came in at -$11.18 falling short of the estimated -$1.43 by -681.82%, while revenue for the quarter reached $222.20M , missing expectations by -33.03%.
Earnings released on 4 Nov 2021
EPS came in at -$4.31 falling short of the estimated -$4.04 by -6.68%, while revenue for the quarter reached $178.84M , missing expectations by -46.55%.
Earnings released on 5 Aug 2021
EPS came in at -$4.75 falling short of the estimated -$3.76 by -26.33%, while revenue for the quarter reached $298.02M , missing expectations by -23.17%.
Earnings released on 10 May 2021
EPS came in at -$3.05 falling short of the estimated -$2.65 by -15.09%, while revenue for the quarter reached $447.23M , missing expectations by -13.25%.
Earnings released on 1 Mar 2021
EPS came in at -$2.70 falling short of the estimated -$1.53 by -76.47%, while revenue for the quarter reached $279.66M .
Earnings released on 9 Nov 2020
EPS came in at -$3.21 falling short of the estimated $2.36 by -236.02%, while revenue for the quarter reached $157.02M , missing expectations by -71.18%.
NVAX Stock Performance
Access detailed NVAX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.